Table 4 Complication rates of RAPN versus OPN
Study (OPN/RAPN) | Patients | Overall complication (%) | Intracomplication (%) | Postcomplication (%) | Clavien1 (%) | Clavien2 (%) | Clavien3 (%) | Clavien4 (%) | Clavien5 (%) | Minor (%) | Major (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
Wu et al. [10] | 94/51 | 18 (19.1)/14 (25.9) | 1 (1.1)/1 (2.0) | 17 (18.1)/13 (25.5) | 16 (17.0)/12a | 1 (1.1)/1 (2.0)b | 16 (17.0)/12 (23.5) | 1 (1.1)/1 (2.0) | |||
Vittori et al. [11] | 198/105 | 58 (29.3)/12 (11.4) | 10 (5.1)/3 (2.9) | 48 (24.2)/9 (8.6) | 3 (1.5)/1 (1.1) | 21 (10.6)/4 (3.8) | 15 (7.6)/1 (1.0) | 3 (1.5)/0 (0.0) | NA/NA | 24 (12.1)/5 (4.8) | 18 (9.1)/1 (1.0) |
Masson-Lecomte et al. [16] | 58/42 | 8 (13.8)/4 (9.6) | NA/NA | 8 (13.8)/4 (9.6) | 0 (0.0)/2 (4.8) | 6 (10.3)/2 (4.8) | 2 (3.4)/0 (0.0) | NA/NA | NA/NA | 6 (10.3)/4 (9.5) | 2 (3.4)/0 (0.0) |
Ficarra et al. [17] | 200/200 | 46 (23.0)/29 (14.5) | 3 (1.5)/1 (0.5) | 43 (21.5)/28 (14.0) | 34 (17.0)/19 (9.5)a | 7 (3.5)/8 (4.0) | 2 (1.0)/1 (0.5) | NA/NA | 34 (17.0)/19 (9.5) | 9 (4.5)/9 (4.5) | |
Kim et al. [24] | 83/67 | 16 (19.3)/10 (14.9) | NA/NA | 16 (19.3)/10 (14.9) | 1 (1.2)/0 (0.0) | 13 (15.7)/7 (10.5) | 0 (0.0)/2 (3.0) | 1 (1.2)/1 (1.5) | 1 (1.2)/0 (0) | 14 (16.9)/7 (10.4) | 2 (2.4)/3 (4.5) |
Lucas et al. [18] | 54/27 | 11 (20.4)/5 (18.5) | 4 (7.4)/1 (3.7) | 7 (13.0)/4 (14.8) | 5 (9.3)/1 (3.7) | 1 (1.9)/2(7.4) | 1 (1.9)/0 (0.0) | 0 (0.0)/1 (3.7) | NA/NA | 6 (11.1)/3 (11.1) | 1 (1.9)/1 (3.7) |
Han et al. [6] | 354/147 | 28 (7.9)/5 (3.4) | NA/NA | 28 (7.9)/5 (3.4) | 4 (1.1)/2 (1.4) | 17 (4.8)/1 (0.7) | 7 (2.0)/2 (0.2)c | NA/NA | 21 (5.9)/3 (2.0) | 7 (2.0)/2 (0.2) | |
Oh et al. [19] | 100/100 | 11 (11.0)/14 (14.0) | 3 (3.0)/4 (4.0) | 8 (8.0)/10 (10.0) | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |
Lee et al. [9] | 234/69 | 46 (19.6)/9 (13.0) | 10 (4.3)/3 (4.3) | 36 (15.4)/6 (8.7) | 20 (8.5)/3 (4.3) | 5 (2.1)/3 (4.3) | 11 (4.7)/0 (0.0) | NA/NA | NA/NA | 25 (10.7)/6 (8.7) | 11 (4.7)/0 (0.0) |
Alemozaffar et al. [7] | 25/25 | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |
Simhan et al. 1 2012 [12] | 136/81 | 68 (50.0)/29 (35.8) | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |
Simhan et al. 2 2012 [12] | 54/10 | 35 (64.8)/8 (80.0) | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |
Zargar et al. 1 2014 [20] | 33/30 | 16 (48.5)/10 (33.3) | 0 (0.0)/1 (3.3) | 16 (48.5)/9 (30.0) | 6 (18.2)/3 (10) | 3 (9.1)/4 (13.3) | 3 (9.1)/2 (6.7) | 4 (12.1)/0 (0.0) | NA/NA | 9 (27.3)/7 (23.3) | 7 (13.5)/2 (6.7) |
Zargar et al. 2 2014 [20] | 52/10 | 21 (40.4)/5 (50.0) | 1 (1.9)/1 (10.0) | 20 (38.5)/4 (40.0) | 10 (19.2)/0 (0) | 4 (7.7)/0 (0.0) | 3 (5.8)/1 (10.0) | 3 (5.8)/3 (30.0) | NA/NA | 14 (26.9)/0 (0.0) | 6 (11.5)/4 (40.0) |
Boylu et al. [8] | 20/46 | 4 (20)/8 (17.3) | 0 (0.0)/0 (0.0) | 4 (20)/8 (17.3) | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |
Mano et al. [22] | 190/63 | 25 (13)/4 (6) | NA/NA | 25 (13)/4 (6) | 14 (7)/4 (6)a | 11 (6)/0 (0) | 0 (0.0)/0 (0.0) | 0 (0.0)/0 (0.0) | 14 (7)/4 (6) | 11 (6)/0 (0) | |
Miyake et al. [23] | 15/16 | 3 (20.0)/1(8.3) | NA/NA | 3 (20.0)/1(8.3) | 1 (6.7)/0 (0)a | 2 (13.3)/1 (8.3)b | 1 (6.7)/0 (0) | 2 (13.3)/1 (8.3) | |||
Webb et al. [21] | 21/14 | 1 (4.7)/1 (7.14) | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA | NA/NA |